30 July, 2017
Hsbc Public Ltd Com owns 1.75M shares. The SI to Agile Therapeutics Incorporated's float is 27.26%.
About 3,800 shares traded.
The stock of Agile Therapeutics Inc (NASDAQ:AGRX) is a huge mover today! It has underperformed by 65.41% the S&P500.The move comes after 6 months negative chart setup for the $122.29 million company. After $-0.26 actual EPS reported by Agile Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth. About 499,706 shares traded. ArQule, Inc. (NASDAQ:ARQL) has declined 22.70% since July 28, 2016 and is downtrending. It has underperformed by 16.70% the S&P500.
Among 19 analysts covering Qualys (NASDAQ:QLYS), 7 have Buy rating, 1 Sell and 11 Hold. Therefore 55% are positive. Agile Therapeutics had 7 analyst reports since December 30, 2015 according to SRatingsIntel. On Friday, July 14 the stock rating was maintained by RBC Capital Markets with "Buy". The firm has "Buy" rating by Noble Financial given on Monday, June 12.
08/09/2016 - Agile Therapeutics, Inc. had its " rating reiterated by analysts at Noble Financial. The firm has "Buy" rating given on Thursday, November 24 by Deutsche Bank. The firm has "Buy" rating given on Friday, July 28 by H.C. Wainwright.
Let's take an assessment at how Agile Therapeutics, Inc. The company has market cap of $83.95 million. The Company is focused in the development and commercialization of prescription contraceptive products. It now has negative earnings. The Company has developed a transdermal patch technology, called Skinfusion.
Renaissance Technologies increased its position in Agile Therapeutics, (NASDAQ:AGRX) by 209.2% throughout the Q4, based on the latest 13F document with the SEC (SEC). Its up 0.11, from 1.74 in 2016Q3. Agile Therapeutics has a one year low of $1.82 and a one year high of $8.15. 9 funds opened positions while 23 raised stakes. Jpmorgan Chase And reported 0% stake.
Analysts await Agile Therapeutics Inc (NASDAQ:AGRX) to report earnings on August, 14.
Hedge funds have recently bought and sold shares of the stock. Moreover, Aisling Capital Llc has 2.39% invested in the company for 1.80 million shares. Rice Hall James & Associates Ltd Liability reported 30,851 shares stake. Everpoint Asset Ltd Co holds 200,000 shares or 0.02% of its portfolio. The Delaware-based Blackrock Advsrs Lc has invested 0% in Agile Therapeutics Inc (NASDAQ:AGRX). 99,225 are held by Granahan Management Incorporated Ma. Alpinvest Partners B.V., a Netherlands-based fund reported 27,693 shares.#img1#. Considering that the stock daily volume of 0.91 million shares, this represents a pretty noteworthy shoot in volume. Citigroup holds 0% of its portfolio in Agile Therapeutics Inc (NASDAQ:AGRX) for 3,467 shares. Dimensional Fund Advsr L P invested 0.01% of its portfolio in Qualys Inc (NASDAQ:QLYS). 9,400 are owned by New York State Common Retirement Fund. Commonwealth Of Pennsylvania School Empls Retrmt Systems owns 30,769 shares or 0% of their U.S. portfolio. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company's stock. The firm has "Strong Buy" rating by Needham given on Tuesday, January 17. The firm has "Overweight" rating given on Thursday, March 31 by JP Morgan. On Friday, August 14 the stock rating was maintained by RBC Capital Markets with "Outperform". Finally, Royal Bank Of Canada set a $8.00 target price on shares of Agile Therapeutics and gave the stock a "buy" rating in a report on Sunday, July 16th. (NYSE:AAP) rating on Friday, February 12. Goldman Sachs has "Neutral" rating and €107 target. Abrams Bison Investments Llc owns 3.02 million shares or 20.46% of their United States portfolio. The rating was maintained by Jefferies with "Hold" on Monday, June 26.
Fabrinet provides optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of products, such as optical communication components, modules and sub-systems, industrial lasers, medical devices and sensors.
Columbia Sportswear Company (NASDAQ:COLM)'s shares may have a significant upside to the consensus target of 63.63, but how has it been performing relative to the market? The Firm designs, makes and markets a range of lenses to improve and protect eyesight. It has a 45.45 P/E ratio.
